Alnylam Q1 net product revs $1.04B (+121%); GAAP EPS $1.51 vs -$0.14; reaffirms FY26 guidance

ALNYLAM PHARMACEUTICALS, INC.

Global net product revenues $1,036M, up 121% YoY; total TTR revenues $910M (+153%).
GAAP net income $206M vs loss $18M; GAAP diluted EPS $1.51; non-GAAP EPS $1.99.
Reiterates FY26 combined net product revenue guidance of $4.9B-$5.3B.
AMVUTTRA (vutrisiran) net product revenues $890M; TRITON-CM expanded to ~1,750 patients.
Initiated Phase 1 obesity trial (ALN-2232) and new collaborations with Viz.ai, AHA, Tenaya, Helix.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALNYLAM PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2026 results: revenue $1,036 Million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $1,036 Million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress − Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-028601

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.